TDF and LdT in Immune-tolerant CHB Patients Awaiting Assisted Reproduction

Summary

Immune-tolerant patients with chronic hepatitis B (CHB) awaiting assisted reproduction (AR) are required to initiate antiviral therapy due to laboratory safety. Additionally, rapid virus elimination is suggested to faciliate timely performance of AR. However, no consensus is reached regarding the antiviral therapy in this group. This study aimed to explore the efficacy and safety of tenofovir (TDF) and telbivudine (LdT) in this population.

Timeline

Start

2014-10

Primary completion

2016-10

Completion

2017-10

Drugs

Indications